Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon May 11, 2022 8:59am
67 Views
Post# 34673419

RE:RE:RE:Nice buy-backs !!!!

RE:RE:RE:Nice buy-backs !!!!
gudisgood wrote:
EbbFlow88 wrote: The volume has been good the last couple days. I'm sure they've been buying even more. Excited for earnings this week!


We're steady approaching 115 million outstanding shares. If the shares are undervalued -- which I certainly believe them to be, and Goodman/Samira seem to agree -- they keep adding value to shareholders (potentially significant value!) with this extremely simple action.

At the same time, I do hope they find other productive uses for the money soon. Whenever they spend on money share buybacks, it means that's the best use of money they can think of. It's great to take an advantage of the share price... but it would be even nicer if they had better opportunities. :)



Exactly - buybacks are the quickest and easiest way for them to help shareholders right now - to prepare for the time when shareholders find Knight in favor.

They do have expectations to use the shelf prospectus but only if it's at higher valuation than the last deal.  No green light to use the shelf prospectus unless we're above the $12-$15 range (IMO).

Focus is likely on selling our present wares and EXELON is at the top of that list.  Lots of potential on the selling side.  I am assuming Knight is trying to prove to Novartis that they are the partner of choice in LATAM - side game going on here.

At this time, the most likely acquisitions will be small - individual drugs, until the timing and price is right for something bigger.  We have enough cash and cashflow coming for small acquisitions while we focus on the art of selling ... and ... continue to whittle down the share count.  That also buys time as they develop the branded generics portfolio.  The options and directions are growing - the more tools they have, the merrier it will be for this company in the future.

It is obviouls that the base is so much bigger and so much stronger than what they created the first time.  It's just slow - a drug licensing characteristic (in the early years) that you are not going to escape (like gravity).


<< Previous
Bullboard Posts
Next >>